Drug Trial Radar · NCT06189404
Effect of Tigulixostat on the Pharmacokinetics of Theophylline
Last checked: Nov 20, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Oct 31, 2023
Primary completion
Nov 13, 2023
Study completion Nov 30, 2023
Sponsor
- Lead sponsor
- LG ChemIndustry
- Sponsor type
- Industry
- First posted
- Jan 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A phase 1, open-label, drug-drug interaction study to evaluate the effect of multiple doses of tigulixostat on the pharmacokinetics of single-dose theophylline in healthy adult volunteers.
Conditions
- Gout
- Hyperuricemia
Interventions
TigulixostatDrug
300 mg oral dose
TheophyllineDrug
400 mg oral dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC0-t of theophylline with and without tigulixostatTime frame: Up to 72 hours
- AUC0-inf of theophylline with and without tigulixostatTime frame: Up to 72 hours
- Cmax of theophylline with and without tigulixostatTime frame: Up to 72 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD - Austin Research Unit
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.